KIORA PHARMACEUTICALS INC Quarterly Debt-to-equity in % from Q1 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kiora Pharmaceuticals Inc quarterly Debt-to-equity history and growth rate from Q1 2017 to Q3 2024.
  • Kiora Pharmaceuticals Inc Debt-to-equity for the quarter ending September 30, 2024 was 30.1 %, a 52.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 30.1 -33.8 -52.9% Sep 30, 2024
Q2 2024 37.3 -21.8 -36.9% Jun 30, 2024
Q1 2024 46.5 -20.8 -30.9% Mar 31, 2024
Q4 2023 73.7 +8.15 +12.4% Dec 31, 2023
Q3 2023 63.9 +6.79 +11.9% Sep 30, 2023
Q2 2023 59.1 +10.5 +21.6% Jun 30, 2023
Q1 2023 67.3 +21.1 +45.7% Mar 31, 2023
Q4 2022 65.5 +20.3 +44.9% Dec 31, 2022
Q3 2022 57.1 +8.2 +16.8% Sep 30, 2022
Q2 2022 48.6 -5.29 -9.82% Jun 30, 2022
Q1 2022 46.2 -4.39 -8.68% Mar 31, 2022
Q4 2021 45.2 -0.19 -0.42% Dec 31, 2021
Q3 2021 48.9 +5.77 +13.4% Sep 30, 2021
Q2 2021 53.9 +8.34 +18.3% Jun 30, 2021
Q1 2021 50.6 +8.58 +20.4% Mar 31, 2021
Q4 2020 45.4 +5.96 +15.1% Dec 31, 2020
Q3 2020 43.1 +0.81 +1.91% Sep 30, 2020
Q2 2020 45.5 +4.76 +11.7% Jun 30, 2020
Q1 2020 42 -1.13 -2.62% Mar 31, 2020
Q4 2019 39.4 -17.9 -31.3% Dec 31, 2019
Q3 2019 42.3 -76.2 -64.3% Sep 30, 2019
Q2 2019 40.8 -204 -83.3% Jun 30, 2019
Q1 2019 43.1 -553 -92.8% Mar 31, 2019
Q4 2018 57.4 -2.63K -97.9% Dec 31, 2018
Q3 2018 119 -1.27K -91.5% Sep 30, 2018
Q2 2018 245 -455 -65% Jun 30, 2018
Q1 2018 596 +148 +33.1% Mar 31, 2018
Q4 2017 2.69K Dec 31, 2017
Q3 2017 1.39K Sep 30, 2017
Q2 2017 699 Jun 30, 2017
Q1 2017 448 Mar 31, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.